Combination drug therapy for relapsed mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of medications for mantle cell lymphoma that has returned or not responded to other treatments. The goal is to see if this combination can shrink tumors and is safe for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have mantle cell lymphoma that has come back or not responded to at least one prior treatment, including a BTK inhibitor (like ibrutinib).
- You must be able to swallow pills.
- Your blood counts, liver, and kidney function must be within certain levels (your doctor will check with blood tests).
- You cannot have an active infection like HIV, hepatitis B, or hepatitis C.
- If you can become pregnant, you must agree to use two effective birth control methods during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This trial tests a new combination of two drugs, nemtabrutinib (a targeted pill) and rituximab (an antibody infusion), for people with mantle cell lymphoma (MCL) who haven't had prior treatment. The goal is to see how well these drugs work together to control the lymphoma.
This trial is testing a combination of three drugs (polatuzumab vedotin, bendamustine, and rituximab) for people with mantle cell lymphoma that has progressed after a BTK inhibitor. The goal is to see if this combination can help control the lymphoma. You'll receive the treatment intravenously (by IV) over several cycles.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
This study tests a combination of three drugs (glofitamab, orelabrutinib, and bortezomib) to see if it is safe and effective for people with a fast-growing or hard-to-treat type of mantle cell lymphoma. If you have high-risk features, this therapy might be an option.
Hear when a new Recurrent Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.